At a glance
Effects
- Fat oxidation / fat loss: REV-ERB activation suppresses lipid-storage gene expression and increases fatty acid oxidation in skeletal muscle and liver; animal models showed significant body-fat reduction [2][5].
- Endurance & exercise capacity: Preclinical studies in mice demonstrated markedly increased running endurance, attributed to higher mitochondrial density and metabolic efficiency in muscle tissue [2][6].
- Metabolic rate: SR9011 is reported to increase energy expenditure (~5%) through enhanced oxygen consumption; it also improves insulin sensitivity and lowers plasma glucose in animal models [1][5].
- Anti-inflammatory action: REV-ERB activation downregulates inflammatory gene expression, including IL-6 in microglia; this effect may contribute to faster post-exercise recovery [4][7].
- Lean-muscle support: Preclinical data indicate increased lean muscle development; unlike androgens, this is non-hormonal and does not involve testosterone suppression [2][3].
- Circadian rhythm modulation: SR9011 alters core clock gene expression (increasing Per2 amplitude, suppressing Cry2), which may affect sleep-wake cycles and energy timing [1][7].
REV-ERBα/β agonist (circadian nuclear receptor modulator; research chemical)
~4 hours (requires 3–4 daily doses)
Oral (capsule / liquid); transdermal investigated for bioavailability
None — no FDA approval, no human clinical trials
Prohibited — REV-ERB agonists banned in sport (same class as SR9009)
About SR9011
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
SR9011 is a synthetic REV-ERBα/β agonist — a circadian-clock nuclear-receptor modulator, not a SARM or hormone — developed at The Scripps Research Institute as a research tool to study metabolism, circadian biology, and inflammation [1][2]. It is sold as a research chemical with no FDA approval or sanctioned human use [3].
How it works
SR9011 binds to and activates the nuclear receptors REV-ERBα and REV-ERBβ, which are core components of the circadian clockwork [4]. These receptors are transcriptional repressors: when activated by SR9011, they recruit the corepressor NCoR and suppress genes related to fat storage, glucose production, Bmal1 expression, and inflammatory signalling [1][4][5]. The practical result is enhanced mitochondrial activity, increased fatty acid and glucose oxidation in skeletal muscle, and improved energy expenditure — effects sometimes described as partially mimicking exercise [2][6].
Risks & side effects
Most important: SR9011 has never undergone human clinical trials; its long-term safety, toxicity profile, and optimal human dosing are entirely unknown [3][8]. Related REV-ERB agonist compounds raise preclinical concerns about genotoxicity and circadian disruption — risks that cannot be ruled out for SR9011 in humans [6][8].
Common
- Insomnia / difficulty sleeping — REV-ERB activation increases wakefulness and can cause hyperactivity, especially with late-day dosing [3][8]
- Increased energy / restlessness — some users report feeling overstimulated [3]
- Frequent dosing burden — ~4 h half-life requires 3–4 daily doses to maintain effect [1][9]
Serious
- Circadian rhythm disruption — sustained REV-ERB agonism can alter the intracellular clock machinery in microglia and other tissues, with unclear systemic consequences [7]
- Unknown toxicity profile — no human safety trials exist; liver and genotoxicity signals observed with closely related REV-ERB agonists cannot be excluded [8][10]
- Unverified product purity — sold as a research chemical; products are frequently underdosed or contaminated with unlisted substances [3]
Rare
- Immune dysregulation — preclinical data show SR9011 modulates microglial immune-metabolic function; implications for human immune response are unknown [7]
- Interaction with cancer biology — REV-ERB agonists selectively kill oncogene-induced senescent and cancer cells in vitro; unknown implications if used by individuals with undiagnosed neoplasia [1]
Safety & harm reduction
- Anyone under 18 years of age — no safety data whatsoever [8]
- Pregnant or breastfeeding individuals — circadian/metabolic disruption poses unknown fetal risk [8]
- Individuals with existing liver disease — related REV-ERB compounds carry preclinical hepatotoxicity signals [10]
- Competitive athletes subject to WADA testing — REV-ERB agonists are on the Prohibited List [10]
- Individuals with diagnosed cancer or pre-cancerous conditions — SR9011 has cytotoxic activity against senescent/cancerous cells with unknown systemic effects [1]
- Liver function tests (ALT, AST, bilirubin) — preclinical concerns with related compounds [10]
- Lipid panel (LDL/HDL) — REV-ERB modulates hepatic lipid metabolism [5]
- Fasting blood glucose / insulin sensitivity — metabolic receptor modulation may alter glucose homeostasis [5]
- Sleep quality — track insomnia or wakefulness changes and adjust dosing timing [3][8]
- Anticoagulants / blood thinners — REV-ERB regulates heme metabolism; interaction potential unknown [7]
- Immunosuppressants — SR9011 modulates immune-metabolic function in microglia; additive or antagonistic effects cannot be excluded [7]
- Other SARMs or metabolic modulators — combined effects are untested and unpredictable [3]
- Medications metabolised via CYP enzymes — hepatic REV-ERB activation may affect CYP rhythmicity; no human data available [8]
- No PCT required — SR9011 is non-hormonal and does not suppress testosterone production [3][9]
- Split dosing strongly advised — due to ~4 h half-life, divide total daily dose into 3–4 equal administrations [1][9]
- Avoid late-evening doses — REV-ERB agonism increases wakefulness; last dose should be taken before early evening [3]
- Cycle length — community practice suggests ≤8 weeks with equivalent time off; no clinical basis exists for this guideline [9]
- Source verification — obtain third-party COA (certificate of analysis) confirming identity and purity before use [3]
Dosage context
No human clinical dosing has ever been formally established [3][8]. Anecdotally-reported ranges in the bodybuilding community are 10–30 mg/day, typically split into 3 doses across the day to account for the ~4 h half-life; beginners commonly start at 10 mg/day [9]. These figures are community-derived, not evidence-based, and should not be treated as safe or recommended doses.
Sources
- 1.Grokipedia — SR9011 pharmacology summary
- 2.Peptides Supply — SR9011 REV-ERB agonist overview (link unavailable)
- 3.sarms.io — SR9011 review (legality, bioavailability, side effects)
- 4.PMC — REV-ERB agonist SR9009 mast cell study (REV-ERB mechanism)
- 5.PMC — REV-ERBα SR9009 goldfish energy balance (metabolic effects)
- 6.Frontiers in Immunology — SR9011 microglia immune-metabolism (PMC)
- 7.Frontiers in Immunology — SR9011 microglia (full article)
- 8.MedXDrg — SR9009/REV-ERB safety overview (genotoxicity, WADA)
- 9.iSARMS forum — SR9011 dosing and half-life (community cross-check)
- 10.MuscleAndBrawn — SR9011 bodybuilding guide (dosing, cycle length)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Substance reviews(4)
Independent reviews of this compound from the wider market — about the substance, not our delivery. Showing the 3 with written feedback.
- ★★★★★11 months ago
Perfect every time
- ★★★★★1 year ago
Muy rpido, perfecto
- ★★★★★1 year ago
Perfecto